Gothenburg, Sweden, 2015-01-27 15:10 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the European Patent Office (EPO) has announced its intention to grant a patent pertaining to the production method of the Company's therapeutic cancer vaccines.
– We are pleased with the positive news from the European Patent Office, which will further strengthen the intellectual property protection for our therapeutic cancer vaccines, says Jamal El-Mosleh, CEO of Immunicum.
The announcement from the EPO relates to a patent titled “Co-Differentiation Of Monocytes From Allogeneic Donors”, covering a significant part of the production method of Immunicum’s therapeutic cancer vaccines.
Immunicum’s vaccine cells are comprised of white blood cells from healthy blood donors, so-called allogeneic dendritic cells, which via a unique refinement process are developed into highly immunogenic cells. The Company's unique vaccine concept is based on over 30 years of research in the field of transplantation immunology and uses a new method to activate the body's own immune system to attack tumor cells.
For further information, please contact:
Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com
The company’s Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se
About Immunicum AB (publ)
Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the company's most advanced project - INTUVAX® against renal cancer - is expected to start in early 2015. The project portfolio contains three further projects, including a clinical phase I/II-study in liver cancer.